Based on the measurements of operating efficiency obtained from Sellas Life's historical financial statements, Sellas Life Sciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Sellas Life's Long Term Debt is comparatively stable compared to the past year. Key indicators impacting Sellas Life's financial strength include:
The essential information of the day-to-day investment outlook for Sellas Life includes many different criteria found on its balance sheet. An individual investor should monitor Sellas Life's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Sellas Life.
Net Income
(39.21 Million)
Sellas
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Cash Conversion Cycle
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Depreciation
Stock Based Compensation
Sale Purchase Of Stock
Dividends Paid
Net Borrowings
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Total Stockholder Equity
Net Debt
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Current Assets
Other Current Liab
Total Current Liabilities
Property Plant And Equipment Net
Retained Earnings
Accounts Payable
Non Current Assets Total
Non Currrent Assets Other
Common Stock Total Equity
Short Term Investments
Other Current Assets
Total Liab
Property Plant And Equipment Gross
Common Stock
Short Long Term Debt Total
Current Deferred Revenue
Non Current Liabilities Total
Accumulated Other Comprehensive Income
Short Term Debt
Net Tangible Assets
Good Will
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Capital Lease Obligations
Non Current Liabilities Other
Intangible Assets
Property Plant Equipment
Other Assets
Long Term Debt
Inventory
Deferred Long Term Liab
Net Receivables
Other Liab
Short Long Term Debt
Net Invested Capital
Net Working Capital
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Depreciation And Amortization
Selling General Administrative
Selling And Marketing Expenses
Gross Profit
Cost Of Revenue
Total Other Income Expense Net
Income Tax Expense
Total Revenue
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Discontinued Operations
Tax Provision
Interest Income
Net Interest Income
Probability Of Bankruptcy
Understanding current and past Sellas Life Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sellas Life's financial statements are interrelated, with each one affecting the others. For example, an increase in Sellas Life's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Sellas Life's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sellas Life Sciences. Check Sellas Life's Beneish M Score to see the likelihood of Sellas Life's management manipulating its earnings.
Sellas Life Stock Summary
Sellas Life competes with Lyra Therapeutics, Hookipa Pharma, SAB Biotherapeutics, Cadrenal Therapeutics,, and Monopar Therapeutics. SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company was founded in 2012 and is headquartered in New York, New York. Sellas Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Sellas Life's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Sellas Life's current stock value. Our valuation model uses many indicators to compare Sellas Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sellas Life competition to find correlations between indicators driving Sellas Life's intrinsic value. More Info.
Sellas Life Sciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Sellas Life's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sellas Life by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Sellas Life Sciences Systematic Risk
Sellas Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sellas Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Sellas Life Sciences correlated with the market. If Beta is less than 0 Sellas Life generally moves in the opposite direction as compared to the market. If Sellas Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sellas Life Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sellas Life is generally in the same direction as the market. If Beta > 1 Sellas Life moves generally in the same direction as, but more than the movement of the benchmark.
Sellas Life Thematic Clasifications
Sellas Life Sciences is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Today, most investors in Sellas Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sellas Life's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Sellas Life growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Sellas Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sellas Life Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sellas Life Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Sellas Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sellas Life's daily price indicators and compare them against related drivers.
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.